"10.1371_journal.pone.0058181","plos one","2013-03-05T00:00:00Z","Ping He; Pengtao Li; Qian Hua; Yuan Liu; Matthias Staufenbiel; Rena Li; Yong Shen","Center for Advanced Therapeutic Strategies of Brain Disorders, Roskamp Institute, Sarasota, Florida, United States of America; Department of Pathology, School of Preclinical Medicine, Beijing University of Chinese Medicine, Beijing, China; Novartis Pharm Ltd., Nervous System Research, Basel, Switzerland; Center for Hormone Advanced Science and Education, Roskamp Institute, Sarasota, Florida, United States of America","Contributed reagents/materials/chemical analysis tools, including confirmation of chemical components of Ginsenoside and Geniposide in TLJN: PL QH YL MS. Wrote and revised the manuscript and addressed the questions from the reviewers: PH YS RL. Conceived and designed the experiments: YS PH PL QH RL. Performed the experiments: PH QH. Analyzed the data: PH RL YS.","Matthias Staufenbiel is employed by Novartis Pharm Ltd. APP23 transgenic (20 males and 20 females in each age group) and non-transgenic wild type (20 males and 20 females in each age group) genotypes in our experiment are on the C57BL/6 background, which were provided by Novartis Institute for Biomedical Research. There is a patent of TongLuoJiuNao from Pengtao Li, Qian Hua and Yong Shen for Alzheimer’s Disease treatment to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","03","Ping He","PH",7,TRUE,5,2,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
